Experimental T-Cell therapy takes aim at lymphoma

NCT ID NCT01333046

Ongoing Disease control Sponsor: Baylor College of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-phase trial tests a new therapy for Hodgkin and non-Hodgkin lymphoma that has returned or not responded to standard treatment. Researchers take a patient's own immune cells, train them in the lab to recognize five cancer-specific proteins (tumor-associated antigens), and give them back as an infusion. Some adult patients also receive a drug called azacytidine to help the cells work better. The main goal is to see if this approach is safe and to learn how the immune system responds.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tumor-associated antigen (TAA)-specific cytotoxic T lymphocytes (CTLs), with or without azacytidine
What this could lead to: If successful, this could point toward a new treatment option for lymphoma patients who have not responded to standard therapies.
What could go wrong: This is a very early Phase 1 trial with only 36 participants, so it is primarily testing safety. The therapy may not shrink tumors or work for everyone, and there is a risk of side effects from the T cells or azacytidine.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HODGKIN DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

classic Hodgkin lymphoma Hodgkins lymphoma non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HODGKIN DISEASE HODGKIN LYMPHOMA NON-HODGKIN LYMPHOMA

Contacts and locations

Locations

Houston Methodist Hospital

Houston, Texas, 77030, United States
Texas Children's Hospital

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.